Mindbeam Uses Generative AI to Find Safer Painkillers

Mindbeam AI has published research demonstrating how generative AI can discover safer pain-relief drugs, using acetaminophen as a baseline. The startup evaluated 24 AI-generated drug candidates targeting TRPV1, a pain-signaling receptor, ultimately identifying three promising compounds through efficacy and toxicity screening. The research addresses a critical gap: acetaminophen, taken by over 60 million Americans weekly, is the leading cause of acute liver failure in the US, responsible for roughly half of all cases and 56,000 annual ER visits. Mindbeam joins a well-funded AI drug discovery field that includes Chai Discovery, Converge Bio, and Google DeepMind's AlphaFold.